AVTX Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Avalo Therapeutics, Inc. had $0.1M of revenue in fiscal 2025, down 86.6% on the year before. Over five years, revenue changed β61.2% a year on average.
Last close Β· Oct 23, 2026
$6.93
7.0%Hi! I read Avalo Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β86.6%
No. Sales fell 86.6% last year.
Does it make a profit?
β132,642.4%
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Avalo Therapeutics, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 5, 2026
Thursday Β· in 11 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 6, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 5, 2026 | Q1 '26 | Time not announced | 8-K β |
| Jan 12, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 6, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 7, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 12, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Mar 20, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 7, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Avalo Therapeutics, Inc. had $0.1M of revenue in fiscal 2025, down 86.6% on the year before. Over five years, revenue changed β61.2% a year on average. Its operating margin was β123,601.7%, down 108,066.1Β pts: of every 100 in sales, about β123,602 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Avalo Therapeutics, Inc. lost $78.3M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Avalo Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $54.6M | $13.2M | $7.4M | $135M | $98.3M |
| Current ratio | 3.1x | 0.7x | 1.8x | 20.0x | 8.1x |
| Quick ratio | 3.1x | 0.7x | 1.8x | 20.0x | 8.1x |
| Total assets | $80.2M | $33.4M | $21.0M | $151M | $116M |
| Total liabilities | $57.1M | $44.3M | $13.7M | $17.7M | $33.4M |
| Shareholders' equity | $23.1M | β$10.9M | $7.3M | $133M | $83.0M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Avalo Therapeutics, Inc. passes 1 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 6 / 9 | 1 / 9 | 4 / 7 | 2 / 7 | 3 / 7 | 3 / 7 | 2 / 8 | 2 / 7 | 1 / 7 |
| Accruals ratio | β32.9% | β2.9% | β65.3% | 5.8% | β57.5% | β21.8% | β26.2% | β3.2% | 16.2% | β20.1% |
| Altman Z'' | β56.73 | β0.36 | β7.90 | β10.85 | β21.47 | β13.68 | β38.60 | β59.06 | 2.57 | β8.95 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.2M | $27.8M | $7.0M | $6.8M | $6.7M | $5.4M | $18.1M | $1.9M | $0.4M | $0.1M |
| Gross profit | $1.2M | $27.2M | $3.8M | $7.3M | $6.4M | $3.9M | $14.6M | $0.6M | β | β |
| Research and development | $10.1M | $4.4M | $5.8M | $11.8M | $32.2M | $59.8M | $31.3M | $13.8M | $24.4M | $50.1M |
| Operating income | β$16.1M | $13.9M | β$35.4M | β$16.1M | β$72.8M | β$82.1M | β$37.4M | β$27.4M | β$68.5M | β$72.9M |
| Pretax income | β | β | β | β | β | β | β$41.6M | β$31.5M | β$35.0M | β$78.1M |
| Income tax | $0.0M | $2.0M | β$0.0M | $0.3M | β$2.8M | β$0.2M | $0.0M | $0.0M | $0.1M | $0.2M |
| Net income | β$16.5M | $11.9M | β$40.1M | β$16.1M | β$63.5M | β$84.4M | β$41.7M | β$31.5M | β$35.1M | β$78.3M |
| Net income to common | β$16.5M | $7.8M | $41.7M | β | β | β | β | β$31.5M | β$35.1M | β |
| Diluted EPS | β$1.87 | $0.42 | β$1.20 | β | β | β | β$1,063.00 | β$113.58 | β$20.91 | β$5.84 |
| Diluted shares | 0.01B | 0.02B | 0.03B | β | β | β | 0.00B | 0.00B | 0.01B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | β$14.6M | $12.6M | β$3.1M | β$19.1M | β$40.5M | β$70.9M | β$26.8M | β$30.7M | β$49.1M | β$51.5M |
| Capital expenditure | $0.0M | $0.0M | $0.6M | $0.3M | $0.1M | $0.1M | $0.1M | β | β | β |
| Free cash flow | β$14.6M | $12.6M | β$3.7M | β$19.4M | β$40.6M | β$71.0M | β$26.8M | β | β | β |
| Depreciation and amortization | $0.0M | $0.4M | $4.6M | $3.9M | $1.8M | $1.7M | $0.2M | $0.2M | $0.2M | $0.3M |
| Stock-based compensation | $1.7M | $1.2M | $2.4M | $2.5M | $6.8M | $8.2M | $7.6M | $3.5M | $5.9M | $13.6M |
| Acquisitions | $0.0M | $18.9M | $0.0M | $0.0M | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $5.1M | $2.5M | $10.6M | $3.6M | $18.9M | $54.6M | $13.2M | $7.4M | $135M | $98.3M |
| Total debt | $2.4M | $0.0M | $15.4M | β | β | β | β | β | β | β |
| Loans, net | β | β | β | $4.1M | β | β | β | β | β | β |
| Deposits | $0.1M | β | β | β | β | β | β | β | β | β |
| Current assets | $5.7M | $10.7M | $21.9M | $17.7M | $26.0M | $61.8M | $16.4M | $8.4M | $139M | $105M |
| Current liabilities | $4.3M | $11.1M | $26.2M | $12.2M | $15.2M | $19.9M | $22.1M | $4.6M | $7.0M | $12.9M |
| Inventory | $0.0M | $0.4M | $0.3M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | β |
| Property and equipment, net | $0.0M | $0.0M | $0.6M | $1.4M | β | β | β | β | β | β |
| Goodwill | $0.0M | $12.3M | $14.4M | $14.4M | $14.4M | $14.4M | $14.4M | $10.5M | $10.5M | $10.5M |
| Intangible assets | $0.0M | $17.7M | $3.8M | $2.4M | $1.6M | $0.0M | $0.0M | β | β | β |
| Total assets | $5.8M | $42.8M | $70.3M | $36.1M | $43.8M | $80.2M | $33.4M | $21.0M | $151M | $116M |
| Total liabilities | $5.6M | $14.9M | $49.3M | $15.1M | $19.2M | $57.1M | $44.3M | $13.7M | $17.7M | $33.4M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β | β |
| Shareholders' equity | $0.2M | $27.9M | $20.9M | $21.0M | $24.6M | $23.1M | β$10.9M | $7.3M | $133M | $83.0M |
| Margins | ||||||||||
| Gross margin | 100.0% | 97.7% | 53.6% | 108.4% | 95.5% | 72.4% | 81.0% | 33.3% | β | β |
| Operating margin | β1,394.6% | 49.9% | β503.4% | β239.1% | β1,087.4% | β1,521.6% | β207.4% | β1,421.6% | β15,535.6% | β123,601.7% |
| EBITDA margin | β1,392.3% | 51.5% | β438.6% | β181.5% | β1,059.9% | β1,490.9% | β206.5% | β1,413.4% | β15,497.3% | β123,018.6% |
| Net margin | β1,428.6% | 42.7% | β569.9% | β238.1% | β947.9% | β1,563.1% | β230.8% | β1,639.5% | β7,965.8% | β132,642.4% |
| FCF margin | β1,267.0% | 45.1% | β52.5% | β287.3% | β606.1% | β1,315.4% | β148.7% | β | β | β |
| Returns | ||||||||||
| Return on capital | β | 43.2% | β109.0% | β | β | β | β | β | β | β |
| Return on capital employed | β1,103.6% | 43.8% | β80.3% | β67.4% | β255.3% | β136.2% | β332.7% | β167.0% | β47.7% | β70.4% |
| Return on equity | β7,957.3% | 84.6% | β164.3% | β76.7% | β278.8% | β354.2% | β684.8% | β | β50.1% | β72.4% |
| Return on assets | β285.5% | 48.9% | β70.9% | β30.2% | β159.0% | β136.1% | β73.4% | β116.1% | β40.9% | β58.6% |
| Return on tangible equity | β7,957.3% | β | 1,525.6% | β386.3% | β741.1% | β977.1% | β | β | β28.7% | β107.9% |
| Growth | ||||||||||
| Revenue growth | β | 2,312.2% | β74.7% | β4.0% | β0.8% | β19.4% | 234.4% | β89.3% | β77.1% | β86.6% |
| Net income growth | β | β | β437.4% | β | β | β | β | β | β | β |
| EPS growth | β | β | β385.7% | β | β | β | β | β | β | β |
| FCF growth | β | β | β129.4% | β | β | β | β | β | β | β |
| Share count change | β | 112.4% | 85.4% | β | β | β | β | 608.4% | 2,599.5% | 78.8% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β0.2x | β | β | β | β | β | β | β | β |
| Debt / equity | 11.4x | 0.0x | 0.7x | β | β | β | β | β | β | β |
| Current ratio | 1.3x | 1.0x | 0.8x | 1.5x | 1.7x | 3.1x | 0.7x | 1.8x | 20.0x | 8.1x |
| Quick ratio | 1.3x | 0.9x | 0.8x | 1.5x | 1.7x | 3.1x | 0.7x | 1.8x | 20.0x | 8.1x |
| Capital allocation | ||||||||||
| Capex / revenue | 3.0% | 0.1% | 8.0% | 3.9% | 0.9% | 2.1% | 0.5% | β | β | β |
| Stock comp / revenue | 147.0% | 4.2% | 34.6% | 37.5% | 101.3% | 151.4% | 41.8% | 180.7% | 1,327.0% | 23,086.4% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 6.0 | 1.0 | 4.0 | 2.0 | 3.0 | 3.0 | 2.0 | 2.0 | 1.0 |
| Altman Z'' | β56.7 | β0.4 | β7.9 | β10.9 | β21.5 | β13.7 | β38.6 | β59.1 | 2.6 | β9.0 |
| Accruals ratio | β32.9% | β2.9% | β65.3% | 5.8% | β57.5% | β21.8% | β26.2% | β3.2% | 16.2% | β20.1% |
Source: SEC EDGAR XBRL filings (CIK 0001534120). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
